23 Oct 2013 Posted in ABPI statement By Press Office
Stephen added: "As we prepare for new leadership, it is vital that innovation continues to be a top priority so that we can meet the NHS's challenges, and we hope that Simon continues the work already begun by David Nicholson to champion innovation.
"Innovation can help deliver efficient and high quality healthcare through reducing hospital admissions and helping improve the quality of life for patients. Whilst we have seen progress in identifying and breaking down the barriers to innovation in the NHS, there is still much more to be done. At a national level, the rate of progress has been promising; however, we have not seen the same kind of motivation or urgency towards delivery at a local level across the NHS. The leadership changes should act as a catalyst to increase momentum so that we can ensure the latest medicines reach patients in a timely manner."
Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410
Mobile: +44 (0) 7808 641811 or +44 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.